During his speech, Dr. Abdel Ghaffar highlighted the critical role of the national private sector in achieving sustainable health development goals. He lauded HVD's significant contributions over two decades, acknowledging the company as a true partner in the success and evolution of Egypt's healthcare sector. He emphasized that innovative companies like HVD are essential for technological advancement and strengthening the nation's capacity to adapt to global healthcare shifts.
Dr. Abdel Ghaffar affirmed the Egyptian state's belief in partnerships
with the national private sector to enhance the healthcare system. He cited HVD
as an exemplary model of innovation and genuine contribution to improving
healthcare quality, pledging continued government support for companies that strengthen
healthcare infrastructure and improve diagnostic and treatment capabilities,
aligning with Egypt's Vision 2030 for comprehensive and sustainable healthcare.
He outlined the Ministry's two-decade collaboration with HVD,
particularly their investment in human capital. He noted HVD's pivotal role in
supporting national programs and presidential initiatives, including The
National Project for Newborn Screening, Maternal and Fetal Healthcare, The
Premarital Screening Initiative, Early Detection of Genetic Diseases, Participation
in combating epidemics, and Contribution to the National Project for the
Egyptian Genome.
HVD has also been instrumental in developing and modernizing
reference laboratories and research centers, as well as elevating quality
standards in diagnostics and manufacturing. This has significantly improved the
efficiency of healthcare services for citizens. Furthermore, HVD has played a crucial
role in supporting the private health sector by equipping hospitals and
laboratories with the latest analytical and diagnostic technologies, boosting
their competitiveness and expanding access to advanced medical services.
Dr. Abdel Ghaffar added that this collaboration extends to advancing
"personalized medicine" through sophisticated diagnostic solutions,
leading to more accurate diagnoses and sustainably improved treatment outcomes,
consistent with global healthcare trends. In support of scientific research,
HVD has provided cutting-edge tools and technologies in molecular biology,
genetic medicine, and biotechnology to universities and research centers,
fostering the development of national scientific expertise capable of
innovation and regional leadership for Egypt.
Dr. Hisham Seteit emphasized that collaboration with
national companies like HVD underscores the state's commitment to supporting
local industry and advanced medical technology. He affirmed the authority's
dedication to integrating with the private sector to efficiently and
effectively meet the healthcare sector's needs, contributing to drug and
diagnostic security.
Dr. Tamer El-Husseiny, Vice Chairman of the Egyptian Drug
Authority, highlighted the partnership with HVD as a successful model of
scientific innovation and technological application integration. He praised
HVD's significant role in enhancing healthcare system efficiency and ensuring
adherence to the highest quality and safety standards.
Dr. Mohamed Aboul Naga, Chairman of HVD company, stated that since its inception twenty years ago, HVD has prioritized human well-being, striving for real and sustainable change in the healthcare sector across Egypt, the region, and Africa. He stressed that the company's flexibility, deeply ingrained in its daily management culture, has been key to its success. Dr. Aboul Naga explained that HVD designed a flexible operational structure capable of adapting to future needs, ensuring sustainable added value for its partners in both government and private sectors.